Tradestie Institutional Equity Comparison Engine

AQST vs LXRX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LXRX Overall Edge

LXRX Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lexicon Pharmaceuticals, Inc. (LXRX) driven by superior Momentum & Technical, Options & Structure while AQST counters with relative strength in Growth & Margin. Fundamentally, AQST trades at N/M Forward P/E with -114.1% operating margin (-41.0% YoY revenue) versus LXRX at N/M Forward P/E and -147.4% operating margin (-20.7% YoY). In options structure, AQST sits in BREAKDOWN (64th %ile IV; Dealer Gamma Walls on Pro) against LXRX sits in BREAKDOWN (59th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
AQST N/M vs LXRX N/M Fwd P/E
Growth & Margin Winner AQST
Op Margin -114.1% vs -147.4% ยท YoY -41.0% vs -20.7%
Momentum & Technical Winner LXRX
1Y -40.6% vs +5.5% ยท 52W Pos 14% vs 27%
Options & Structure Winner LXRX
BREAKDOWN (64th %ile IV) vs BREAKDOWN (59th %ile IV)
AQST NASDAQ
Aquestive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.46
-6.61% 1D
Market Cap $465.7M
1M Return -16.22%
1Y Return -40.65%
Forward P/E N/M
Unified AI Score
62.9 / 100 BUY
Tech 54.0 Fund 68.0 Flow 68.0 Mom 60.0
LXRX NASDAQ
Lexicon Pharmaceuticals, Inc.
Pharmaceutical Preparations
$1.53
-8.38% 1D
Market Cap $743.5M
1M Return +2.68%
1Y Return +5.52%
Forward P/E N/M
Unified AI Score
48.7 / 100 HOLD
Tech 25.0 Fund 49.0 Flow 69.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AQST -40.65% LXRX +5.52% Spread: +46.17 pp (LXRX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period AQST Revenue LXRX Revenue AQST Op. Margin LXRX Op. Margin Margin Edge
FY2018 $70M $30M -72.6% -388.5% AQST
FY2019 $50M $30M -100.1% 437.5% LXRX
FY2020 $50M $20M -93.6% -204.2% AQST
FY2021 $50M N/A -68.2% N/A AQST
FY2022 $50M N/A -88.2% N/A AQST
FY2023 $50M $0M -29.9% -15473.0% AQST
FY2024 $60M $10M -53.5% -3284.7% AQST
FY2025 $40M $50M -159.5% -98.2% LXRX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AQST (4) vs LXRX (4)
Institutional Metric AQST LXRX Criterion Row Winner
Market Capitalization Scale $465.7M $743.5M Larger Scale LXRX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -41.0% -20.7% Higher Growth LXRX
Operating Margin (TTM) Profitability -114.1% -147.4% Higher Margin AQST
Net Profit Margin Profitability -162.3% -161.8% Higher Margin LXRX
Return on Equity (ROE) Capital Efficiency 0.0% -43.9% Higher ROE AQST
52-Week Range Position Momentum 14% ($3โ€“$7) 27% ($1โ€“$3) Stronger Trend LXRX
Beta / 30D Volatility Risk Regime 0.89ฮฒ ยท 56% Vol 0.85ฮฒ ยท 69% Vol Lower Realized Risk AQST
Unified Institutional Score Composite Signal 62.9 / 100 (BUY) 48.7 / 100 (HOLD) Higher Composite AQST

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AQST vs LXRX Buy Guide
AQST BREAKDOWN
61d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 64th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live AQST Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LXRX BREAKDOWN
102d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 59th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live LXRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AQST nor LXRX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.